Sam Toole is an entrepreneur and operator turned investor with NYC-based Primary Ventures.
In Part 1 of this series, we laid out why we believe AI-native, vertical EHRs could represent one of the more interesting bets in healthcare software right now. We described the structural dynamics that make certain specialties worth targeting: provider independence, workflow complexity, administrative burden, and competitive fragmentation.
We closed with a question we've been spending time on since: does the EHR market need business model innovation to be truly venture scale?
`Upcoming Sessions
Live conversations with the people shaping healthcare.
Is It Finally the Moment for Alternative Plan Design?
Register Here Employers are under growing pressure to control healthcare costs while improving access, outcomes, and the member experience. That has renewed
Type 2 Diabetes & Cardiometabolic Care: Wearables, AI & GLP-1s
Register Here The rise of wearables, GLP-1s, and AI is reshaping treatment for Type 2 diabetes, weight loss, and metabolic disease.
Verifying AI in Medicine: Is Healthcare AI Actually Ready for Deployment?
Is AI ready for real-world clinical care? Dr. Zak Kohane and Protege’s Engy Ziedan debate what it takes to safely trust AI in diagnosis and treatment, from benchmark performance and clinical evidence to whether we’re holding AI to a higher standard than humans.
Why Are Hospitals Hiring Chief AI Officers?
As AI moves from pilots into day-to-day healthcare operations, health systems are having to decide who should actually own the
Where are AI Agents Actually Working in Healthcare, and Why?
While the healthcare industry remains locked in a high-level debate over the theoretical potential of artificial intelligence, a select group of
Top Employers Share What Healthcare Startups Need to Know in 2026
As enterprise health purchasers face volatile medical cost trends and tightening operational margins, the standard vendor pitch of "improved clinical efficiency&
Peptide Therapy: Where Do We Go From Here?
Watch the full webinar Peptide therapies have moved from niche biohacking circles into mainstream medicine, reshaping conversations around weight management, metabolic health,
Not everyone can access the top 1% of physicians. Will AI change that?
Historically, top-tier medical expertise was limited by wealth and geography. As AI reshapes healthcare delivery, a vital question emerges: can it democratize intelligence to give everyone access to the caliber of care typically reserved for the top 1%?
Privacy AI and the Future of HIPAA
Watch the Full Webinar As AI reshapes healthcare and more patient data flows beyond traditional clinical settings, the rules governing privacy, access,